|
1
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdel-Rahman O: Systemic therapy for
hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl
Canc Inst. 25:165–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM and Bruix J: Novel advancements
in the management of hepatocellular carcinoma in 2008. J Hepatol.
48 Suppl 1:S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao
Y, Jiang C and Ding Y: Hepatic stellate cell coculture enables
sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and
Jak2/Stat3 pathways. Biomed Res Int. 2014:7649812014.PubMed/NCBI
|
|
6
|
Moeini A, Cornellà H and Villanueva A:
Emerging signaling pathways in hepatocellular carcinoma. Liver
Cancer. 1:83–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang WS and Yang CH: Sorafenib induced
tumor lysis syndrome in an advanced hepatocellular carcinoma
patient. World J Gastroenterol. 15:4464–4466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
National Comprehensive Cancer Network, .
(NCCN) Clinical Practice Guidelines in Oncology. Hepatobiliary
Cancers. 2008 https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed.
8–Feb;2008.
|
|
9
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S,
Kim JS, Yang TS, Tak WY, Pan H, Yu S, et al: Efficacy and safety of
sorafenib in patients with advanced hepatocellular carcinoma
according to baseline status: Subset analyses of the phase III
Sorafenib Asia-Pacific trial. Eur J Cancer. 48:1452–1465. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morimoto M, Numata K, Kondo M, Kobayashi
S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K,
et al: Field practice study of half-dose sorafenib treatment on
safety and efficacy for hepatocellular carcinoma: A propensity
score analysis. Hepatol Res. 45:279–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vincenzi B, Santini D, Russo A, Addeo R,
Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M,
et al: Early skin toxicity as a predictive factor for tumor control
in hepatocellular carcinoma patients treated with sorafenib.
Oncologist. 15:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mbeunkui F and Johann DJ Jr: Cancer and
the tumor microenvironment: A review of an essential relationship.
Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Deng M, Hu J, Li X, Chen L, Ju Y,
Hao J and Meng S: Chronic inflammation contributes to the
development of hepatocellular carcinoma by decreasing miR-122
levels. Oncotarget. 7:17021–17034. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC,
Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, et al: Inflammation
promotes expression of stemness-related properties in HBV-related
hepatocellular carcinoma. PLoS One. 11:e1498972016.
|
|
16
|
Wang F, Liu ZY, Xia YY, Zhou C, Shen XM,
Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, et al: Changes in
neutrophil/lymphocyte and platelet/lymphocyte ratios after
chemotherapy correlate with chemotherapy response and prediction of
prognosis in patients with unresectable gastric cancer. Oncol Lett.
10:3411–3418. 2015.PubMed/NCBI
|
|
17
|
Pine JK, Morris E, Hutchins GG, West NP,
Jayne DG, Quirke P and Prasad KR: Systemic neutrophil-to-lymphocyte
ratio in colorectal cancer: The relationship to patient survival,
tumour biology and local lymphocytic response to tumour. Br J
Cancer. 113:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szkandera J, Stotz M, Eisner F, Absenger
G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R,
Alzoughbi W, Ress AL, et al: External validation of the derived
neutrophil to lymphocyte ratio as a prognostic marker on a large
cohort of pancreatic cancer patients. PLoS One. 8:e782252013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao N and Cai Q: High pretreatment
neutrophil-lymphocyte ratio predicts recurrence and poor prognosis
for combined small cell lung cancer. Clin Transl Oncol. 17:772–778.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao GQ, Liu C, Liu DL, Yang JY and Yan
LN: Neutrophil-lymphocyte ratio predicts the prognosis of patients
with hepatocellular carcinoma after liver transplantation. World J
Gastroenterol. 19:8398–8407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okamura Y, Ashida R, Ito T, Sugiura T,
Mori K and Uesaka K: Preoperative neutrophil to lymphocyte ratio
and prognostic nutritional index predict overall survival after
hepatectomy for hepatocellular carcinoma. World J Surg.
39:1501–1509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan W, Zhang Y, Wang Y, Yao X, Yang J and
Li J: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as
predictors of survival and metastasis for recurrent hepatocellular
carcinoma after transarterial chemoembolization. PLoS One.
10:e1193122015.
|
|
23
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
133:176–181. 2003. View Article : Google Scholar
|
|
24
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu
F, Liu L, Zhou J, Dou K, Hao C, et al: Safety and efficacy of
sorafenib therapy in patients with hepatocellular carcinoma: Final
outcome from the Chinese patient subset of the GIDEON study.
Oncotarget. 7:6639–6648. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Llovet JM, Peña CE, Lathia CD, Shan M,
Meinhardt G and Bruix J: SHARP Investigators Study Group: Plasma
biomarkers as predictors of outcome in patients with advanced
hepatocellular carcinoma. Clin Cancer Res. 18:2290–2300. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Zhou X, Shen H, Wang D and Wang
Y: Phosphorylated ERK is a potential predictor of sensitivity to
sorafenib when treating hepatocellular carcinoma: Evidence from an
in vitro study. BMC Med. 7:412009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bolondi L, Burroughs A, Dufour JF, Galle
PR, Mazzaferro V, Piscaglia F, Raoul JL and Sangro B: Heterogeneity
of patients with intermediate (BCLC B) Hepatocellular Carcinoma:
Proposal for a subclassification to facilitate treatment decisions.
Semin Liver Dis. 32:348–359. 2012.PubMed/NCBI
|
|
29
|
Kim J and Bae JS: Tumor-associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Motomura T, Shirabe K, Mano Y, Muto J,
Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi
T, et al: Neutrophil-lymphocyte ratio reflects hepatocellular
carcinoma recurrence after liver transplantation via inflammatory
microenvironment. J Hepatol. 58:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu
Z, Yin XY and Zheng L: Peritumoral neutrophils link inflammatory
response to disease progression by fostering angiogenesis in
hepatocellular carcinoma. J Hepatol. 54:948–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kusumanto YH, Dam WA, Hospers GA, Meijer C
and Mulder NH: Platelets and granulocytes, in particular the
neutrophils, form important compartments for circulating vascular
endothelial growth factor. Angiogenesis. 6:283–287. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li XF, Chen DP, Ouyang FZ, Chen MM, Wu Y,
Kuang DM and Zheng L: Increased autophagy sustains the survival and
pro-tumourigenic effects of neutrophils in human hepatocellular
carcinoma. J Hepatol. 62:131–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
